TP53 and hepatocellular carcinoma: These results showed that the cell cycle- and p53-related gene sets could be activated by iberverin, and G2/M DNA damage checkpoint might be a key tumor suppressor checkpoint, indicating the potential regulatory mechanisms of iberverin in terms of its anti-HCC effect.